{
    "matches": [
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "technique": "mass spectrometry",
                    "comparison to": "controls",
                    "statistical representation": "average SC and NSAF ratio",
                    "replicates": "not specified"
                },
                "measures": "[protein name, accession number, MW, average SC, NSAF ratio, P-value]",
                "outcomes": [
                    "[Fibrinogen beta chain isoform 1 pre-pro-protein, 70906435, 56, 138.8, 52.1, 2.2, 0.01481]",
                    "[C4b-binding protein alpha chain precursor, 4502503, 67, 37.3, 11.5, 2.3, 0.04311]",
                    "[Serum albumin pre-pro-protein, 4502027, 69, 986.0, 332.8, 2.4, 0.00006]",
                    "[Vitamin D-binding protein isoform 1 precursor, 32483410, 53, 51.9, 19.2, 2.4, 0.03919]",
                    "[Kininogen-1 isoform 2 precursor, 4504893, 48, 21.3, 5.5, 3.8, 0.01109]",
                    "[Alpha-2-macroglobulin precursor, 66932947, 163, 127.9, 29.3, 3.9, 0.00618]",
                    "[Haptoglobin isoform 1 pre-pro-protein, 4826762, 45, 83.8, 18.0, 4.2, 0.00024]",
                    "[Fibrinogen gamma chain isoform gamma-B precursor, 70906439, 52, 89.3, 17.3, 4.3, 0.00133]",
                    "[Complement C3 precursor, 115298678, 187, 174.7, 35.6, 4.3, 0.00612]",
                    "[Myeloperoxidase precursor, 4557759, 84, 70.2, 11.0, 5.3, 0.02501]",
                    "[Apolipoprotein A-I pre-pro-protein, 4557321, 31, 29.8, 5.9, 5.7, 0.02170]",
                    "[Fibrinogen alpha chain isoform alpha-E pre-pro-protein, 4503689, 95, 63.3, 9.3, 6.4, 0.00031]",
                    "[Alpha-2-HS-glycoprotein pre-pro-protein, 156523970, 39, 7.3, 1.1, 6.5, 0.00173]",
                    "[Ceruloplasmin precursor, 4557485, 122, 47.3, 5.6, 7.5, 0.00114]",
                    "[PREDICTED: complement C4-A isoform 1, 341916194, 193, 32.1, 4.5, 7.7, 0.01791]",
                    "[Alpha-1B-glycoprotein precursor, 21071030, 54, 10.9, 1.2, 8.3, 0.00468]",
                    "[Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor, 31542984, 103, 5.5, 0.2, 35.4, 0.00484]",
                    "[Apolipoprotein B-100 precursor, 105990532, 516, 49.3, 1.0, 55.7, 0.02595]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "protein": "Fibrinogen beta chain isoform 1 pre-pro-protein",
                    "accession": "70906435",
                    "Molecural weight (MW) (kDa)": "56",
                    "statistical test": "t-test"
                },
                "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                "outcomes": "[138.8, 52.1, 2.2, 0.01481]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "technique": "mass spectrometry",
                    "comparison to": "controls",
                    "statistical representation": "average SC and NSAF ratio",
                    "replicates": "not specified"
                },
                "measures": "[protein name, accession number, MW, average SC, NSAF ratio, P-value]",
                "outcomes": [
                    "[Fibrinogen beta chain isoform 1 pre-pro-protein, 70906435, 56, 138.8, 52.1, 2.2, 0.01481]",
                    "[C4b-binding protein alpha chain precursor, 4502503, 67, 37.3, 11.5, 2.3, 0.04311]",
                    "[Serum albumin pre-pro-protein, 4502027, 69, 986.0, 332.8, 2.4, 0.00006]",
                    "[Vitamin D-binding protein isoform 1 precursor, 32483410, 53, 51.9, 19.2, 2.4, 0.03919]",
                    "[Kininogen-1 isoform 2 precursor, 4504893, 48, 21.3, 5.5, 3.8, 0.01109]",
                    "[Alpha-2-macroglobulin precursor, 66932947, 163, 127.9, 29.3, 3.9, 0.00618]",
                    "[Haptoglobin isoform 1 pre-pro-protein, 4826762, 45, 83.8, 18.0, 4.2, 0.00024]",
                    "[Fibrinogen gamma chain isoform gamma-B precursor, 70906439, 52, 89.3, 17.3, 4.3, 0.00133]",
                    "[Complement C3 precursor, 115298678, 187, 174.7, 35.6, 4.3, 0.00612]",
                    "[Myeloperoxidase precursor, 4557759, 84, 70.2, 11.0, 5.3, 0.02501]",
                    "[Apolipoprotein A-I pre-pro-protein, 4557321, 31, 29.8, 5.9, 5.7, 0.02170]",
                    "[Fibrinogen alpha chain isoform alpha-E pre-pro-protein, 4503689, 95, 63.3, 9.3, 6.4, 0.00031]",
                    "[Alpha-2-HS-glycoprotein pre-pro-protein, 156523970, 39, 7.3, 1.1, 6.5, 0.00173]",
                    "[Ceruloplasmin precursor, 4557485, 122, 47.3, 5.6, 7.5, 0.00114]",
                    "[PREDICTED: complement C4-A isoform 1, 341916194, 193, 32.1, 4.5, 7.7, 0.01791]",
                    "[Alpha-1B-glycoprotein precursor, 21071030, 54, 10.9, 1.2, 8.3, 0.00468]",
                    "[Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor, 31542984, 103, 5.5, 0.2, 35.4, 0.00484]",
                    "[Apolipoprotein B-100 precursor, 105990532, 516, 49.3, 1.0, 55.7, 0.02595]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "protein": "C4b-binding protein alpha chain precursor",
                    "accession": "4502503",
                    "Molecural weight (MW) (kDa)": "67",
                    "statistical test": "t-test"
                },
                "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                "outcomes": "[37.3, 11.5, 2.3, 0.04311]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "technique": "mass spectrometry",
                    "comparison to": "controls",
                    "statistical representation": "average SC and NSAF ratio",
                    "replicates": "not specified"
                },
                "measures": "[protein name, accession number, MW, average SC, NSAF ratio, P-value]",
                "outcomes": [
                    "[Fibrinogen beta chain isoform 1 pre-pro-protein, 70906435, 56, 138.8, 52.1, 2.2, 0.01481]",
                    "[C4b-binding protein alpha chain precursor, 4502503, 67, 37.3, 11.5, 2.3, 0.04311]",
                    "[Serum albumin pre-pro-protein, 4502027, 69, 986.0, 332.8, 2.4, 0.00006]",
                    "[Vitamin D-binding protein isoform 1 precursor, 32483410, 53, 51.9, 19.2, 2.4, 0.03919]",
                    "[Kininogen-1 isoform 2 precursor, 4504893, 48, 21.3, 5.5, 3.8, 0.01109]",
                    "[Alpha-2-macroglobulin precursor, 66932947, 163, 127.9, 29.3, 3.9, 0.00618]",
                    "[Haptoglobin isoform 1 pre-pro-protein, 4826762, 45, 83.8, 18.0, 4.2, 0.00024]",
                    "[Fibrinogen gamma chain isoform gamma-B precursor, 70906439, 52, 89.3, 17.3, 4.3, 0.00133]",
                    "[Complement C3 precursor, 115298678, 187, 174.7, 35.6, 4.3, 0.00612]",
                    "[Myeloperoxidase precursor, 4557759, 84, 70.2, 11.0, 5.3, 0.02501]",
                    "[Apolipoprotein A-I pre-pro-protein, 4557321, 31, 29.8, 5.9, 5.7, 0.02170]",
                    "[Fibrinogen alpha chain isoform alpha-E pre-pro-protein, 4503689, 95, 63.3, 9.3, 6.4, 0.00031]",
                    "[Alpha-2-HS-glycoprotein pre-pro-protein, 156523970, 39, 7.3, 1.1, 6.5, 0.00173]",
                    "[Ceruloplasmin precursor, 4557485, 122, 47.3, 5.6, 7.5, 0.00114]",
                    "[PREDICTED: complement C4-A isoform 1, 341916194, 193, 32.1, 4.5, 7.7, 0.01791]",
                    "[Alpha-1B-glycoprotein precursor, 21071030, 54, 10.9, 1.2, 8.3, 0.00468]",
                    "[Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor, 31542984, 103, 5.5, 0.2, 35.4, 0.00484]",
                    "[Apolipoprotein B-100 precursor, 105990532, 516, 49.3, 1.0, 55.7, 0.02595]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "protein": "Serum albumin pre-pro-protein",
                    "accession": "4502027",
                    "Molecural weight (MW) (kDa)": "69",
                    "statistical test": "t-test"
                },
                "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                "outcomes": "[986.0, 332.8, 2.4, 0.00006]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "technique": "mass spectrometry",
                    "comparison to": "controls",
                    "statistical representation": "average SC and NSAF ratio",
                    "replicates": "not specified"
                },
                "measures": "[protein name, accession number, MW, average SC, NSAF ratio, P-value]",
                "outcomes": [
                    "[Fibrinogen beta chain isoform 1 pre-pro-protein, 70906435, 56, 138.8, 52.1, 2.2, 0.01481]",
                    "[C4b-binding protein alpha chain precursor, 4502503, 67, 37.3, 11.5, 2.3, 0.04311]",
                    "[Serum albumin pre-pro-protein, 4502027, 69, 986.0, 332.8, 2.4, 0.00006]",
                    "[Vitamin D-binding protein isoform 1 precursor, 32483410, 53, 51.9, 19.2, 2.4, 0.03919]",
                    "[Kininogen-1 isoform 2 precursor, 4504893, 48, 21.3, 5.5, 3.8, 0.01109]",
                    "[Alpha-2-macroglobulin precursor, 66932947, 163, 127.9, 29.3, 3.9, 0.00618]",
                    "[Haptoglobin isoform 1 pre-pro-protein, 4826762, 45, 83.8, 18.0, 4.2, 0.00024]",
                    "[Fibrinogen gamma chain isoform gamma-B precursor, 70906439, 52, 89.3, 17.3, 4.3, 0.00133]",
                    "[Complement C3 precursor, 115298678, 187, 174.7, 35.6, 4.3, 0.00612]",
                    "[Myeloperoxidase precursor, 4557759, 84, 70.2, 11.0, 5.3, 0.02501]",
                    "[Apolipoprotein A-I pre-pro-protein, 4557321, 31, 29.8, 5.9, 5.7, 0.02170]",
                    "[Fibrinogen alpha chain isoform alpha-E pre-pro-protein, 4503689, 95, 63.3, 9.3, 6.4, 0.00031]",
                    "[Alpha-2-HS-glycoprotein pre-pro-protein, 156523970, 39, 7.3, 1.1, 6.5, 0.00173]",
                    "[Ceruloplasmin precursor, 4557485, 122, 47.3, 5.6, 7.5, 0.00114]",
                    "[PREDICTED: complement C4-A isoform 1, 341916194, 193, 32.1, 4.5, 7.7, 0.01791]",
                    "[Alpha-1B-glycoprotein precursor, 21071030, 54, 10.9, 1.2, 8.3, 0.00468]",
                    "[Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor, 31542984, 103, 5.5, 0.2, 35.4, 0.00484]",
                    "[Apolipoprotein B-100 precursor, 105990532, 516, 49.3, 1.0, 55.7, 0.02595]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "protein": "Vitamin D-binding protein isoform 1 precursor",
                    "accession": "32483410",
                    "Molecural weight (MW) (kDa)": "53",
                    "statistical test": "t-test"
                },
                "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                "outcomes": "[51.9, 19.2, 2.4, 0.03919]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "technique": "mass spectrometry",
                    "comparison to": "controls",
                    "statistical representation": "average SC and NSAF ratio",
                    "replicates": "not specified"
                },
                "measures": "[protein name, accession number, MW, average SC, NSAF ratio, P-value]",
                "outcomes": [
                    "[Fibrinogen beta chain isoform 1 pre-pro-protein, 70906435, 56, 138.8, 52.1, 2.2, 0.01481]",
                    "[C4b-binding protein alpha chain precursor, 4502503, 67, 37.3, 11.5, 2.3, 0.04311]",
                    "[Serum albumin pre-pro-protein, 4502027, 69, 986.0, 332.8, 2.4, 0.00006]",
                    "[Vitamin D-binding protein isoform 1 precursor, 32483410, 53, 51.9, 19.2, 2.4, 0.03919]",
                    "[Kininogen-1 isoform 2 precursor, 4504893, 48, 21.3, 5.5, 3.8, 0.01109]",
                    "[Alpha-2-macroglobulin precursor, 66932947, 163, 127.9, 29.3, 3.9, 0.00618]",
                    "[Haptoglobin isoform 1 pre-pro-protein, 4826762, 45, 83.8, 18.0, 4.2, 0.00024]",
                    "[Fibrinogen gamma chain isoform gamma-B precursor, 70906439, 52, 89.3, 17.3, 4.3, 0.00133]",
                    "[Complement C3 precursor, 115298678, 187, 174.7, 35.6, 4.3, 0.00612]",
                    "[Myeloperoxidase precursor, 4557759, 84, 70.2, 11.0, 5.3, 0.02501]",
                    "[Apolipoprotein A-I pre-pro-protein, 4557321, 31, 29.8, 5.9, 5.7, 0.02170]",
                    "[Fibrinogen alpha chain isoform alpha-E pre-pro-protein, 4503689, 95, 63.3, 9.3, 6.4, 0.00031]",
                    "[Alpha-2-HS-glycoprotein pre-pro-protein, 156523970, 39, 7.3, 1.1, 6.5, 0.00173]",
                    "[Ceruloplasmin precursor, 4557485, 122, 47.3, 5.6, 7.5, 0.00114]",
                    "[PREDICTED: complement C4-A isoform 1, 341916194, 193, 32.1, 4.5, 7.7, 0.01791]",
                    "[Alpha-1B-glycoprotein precursor, 21071030, 54, 10.9, 1.2, 8.3, 0.00468]",
                    "[Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor, 31542984, 103, 5.5, 0.2, 35.4, 0.00484]",
                    "[Apolipoprotein B-100 precursor, 105990532, 516, 49.3, 1.0, 55.7, 0.02595]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "protein": "Kininogen-1 isoform 2 precursor",
                    "accession": "4504893",
                    "Molecural weight (MW) (kDa)": "48",
                    "statistical test": "t-test"
                },
                "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                "outcomes": "[21.3, 5.5, 3.8, 0.01109]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "technique": "mass spectrometry",
                    "comparison to": "controls",
                    "statistical representation": "average SC and NSAF ratio",
                    "replicates": "not specified"
                },
                "measures": "[protein name, accession number, MW, average SC, NSAF ratio, P-value]",
                "outcomes": [
                    "[Fibrinogen beta chain isoform 1 pre-pro-protein, 70906435, 56, 138.8, 52.1, 2.2, 0.01481]",
                    "[C4b-binding protein alpha chain precursor, 4502503, 67, 37.3, 11.5, 2.3, 0.04311]",
                    "[Serum albumin pre-pro-protein, 4502027, 69, 986.0, 332.8, 2.4, 0.00006]",
                    "[Vitamin D-binding protein isoform 1 precursor, 32483410, 53, 51.9, 19.2, 2.4, 0.03919]",
                    "[Kininogen-1 isoform 2 precursor, 4504893, 48, 21.3, 5.5, 3.8, 0.01109]",
                    "[Alpha-2-macroglobulin precursor, 66932947, 163, 127.9, 29.3, 3.9, 0.00618]",
                    "[Haptoglobin isoform 1 pre-pro-protein, 4826762, 45, 83.8, 18.0, 4.2, 0.00024]",
                    "[Fibrinogen gamma chain isoform gamma-B precursor, 70906439, 52, 89.3, 17.3, 4.3, 0.00133]",
                    "[Complement C3 precursor, 115298678, 187, 174.7, 35.6, 4.3, 0.00612]",
                    "[Myeloperoxidase precursor, 4557759, 84, 70.2, 11.0, 5.3, 0.02501]",
                    "[Apolipoprotein A-I pre-pro-protein, 4557321, 31, 29.8, 5.9, 5.7, 0.02170]",
                    "[Fibrinogen alpha chain isoform alpha-E pre-pro-protein, 4503689, 95, 63.3, 9.3, 6.4, 0.00031]",
                    "[Alpha-2-HS-glycoprotein pre-pro-protein, 156523970, 39, 7.3, 1.1, 6.5, 0.00173]",
                    "[Ceruloplasmin precursor, 4557485, 122, 47.3, 5.6, 7.5, 0.00114]",
                    "[PREDICTED: complement C4-A isoform 1, 341916194, 193, 32.1, 4.5, 7.7, 0.01791]",
                    "[Alpha-1B-glycoprotein precursor, 21071030, 54, 10.9, 1.2, 8.3, 0.00468]",
                    "[Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor, 31542984, 103, 5.5, 0.2, 35.4, 0.00484]",
                    "[Apolipoprotein B-100 precursor, 105990532, 516, 49.3, 1.0, 55.7, 0.02595]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "protein": "Alpha-2-macroglobulin precursor",
                    "accession": "66932947",
                    "Molecural weight (MW) (kDa)": "163",
                    "statistical test": "t-test"
                },
                "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                "outcomes": "[127.9, 29.3, 3.9, 0.00618]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "technique": "mass spectrometry",
                    "comparison to": "controls",
                    "statistical representation": "average SC and NSAF ratio",
                    "replicates": "not specified"
                },
                "measures": "[protein name, accession number, MW, average SC, NSAF ratio, P-value]",
                "outcomes": [
                    "[Fibrinogen beta chain isoform 1 pre-pro-protein, 70906435, 56, 138.8, 52.1, 2.2, 0.01481]",
                    "[C4b-binding protein alpha chain precursor, 4502503, 67, 37.3, 11.5, 2.3, 0.04311]",
                    "[Serum albumin pre-pro-protein, 4502027, 69, 986.0, 332.8, 2.4, 0.00006]",
                    "[Vitamin D-binding protein isoform 1 precursor, 32483410, 53, 51.9, 19.2, 2.4, 0.03919]",
                    "[Kininogen-1 isoform 2 precursor, 4504893, 48, 21.3, 5.5, 3.8, 0.01109]",
                    "[Alpha-2-macroglobulin precursor, 66932947, 163, 127.9, 29.3, 3.9, 0.00618]",
                    "[Haptoglobin isoform 1 pre-pro-protein, 4826762, 45, 83.8, 18.0, 4.2, 0.00024]",
                    "[Fibrinogen gamma chain isoform gamma-B precursor, 70906439, 52, 89.3, 17.3, 4.3, 0.00133]",
                    "[Complement C3 precursor, 115298678, 187, 174.7, 35.6, 4.3, 0.00612]",
                    "[Myeloperoxidase precursor, 4557759, 84, 70.2, 11.0, 5.3, 0.02501]",
                    "[Apolipoprotein A-I pre-pro-protein, 4557321, 31, 29.8, 5.9, 5.7, 0.02170]",
                    "[Fibrinogen alpha chain isoform alpha-E pre-pro-protein, 4503689, 95, 63.3, 9.3, 6.4, 0.00031]",
                    "[Alpha-2-HS-glycoprotein pre-pro-protein, 156523970, 39, 7.3, 1.1, 6.5, 0.00173]",
                    "[Ceruloplasmin precursor, 4557485, 122, 47.3, 5.6, 7.5, 0.00114]",
                    "[PREDICTED: complement C4-A isoform 1, 341916194, 193, 32.1, 4.5, 7.7, 0.01791]",
                    "[Alpha-1B-glycoprotein precursor, 21071030, 54, 10.9, 1.2, 8.3, 0.00468]",
                    "[Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor, 31542984, 103, 5.5, 0.2, 35.4, 0.00484]",
                    "[Apolipoprotein B-100 precursor, 105990532, 516, 49.3, 1.0, 55.7, 0.02595]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "protein": "Haptoglobin isoform 1 pre-pro-protein",
                    "accession": "4826762",
                    "Molecural weight (MW) (kDa)": "45",
                    "statistical test": "t-test"
                },
                "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                "outcomes": "[83.8, 18.0, 4.2, 0.00024]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "technique": "mass spectrometry",
                    "comparison to": "controls",
                    "statistical representation": "average SC and NSAF ratio",
                    "replicates": "not specified"
                },
                "measures": "[protein name, accession number, MW, average SC, NSAF ratio, P-value]",
                "outcomes": [
                    "[Fibrinogen beta chain isoform 1 pre-pro-protein, 70906435, 56, 138.8, 52.1, 2.2, 0.01481]",
                    "[C4b-binding protein alpha chain precursor, 4502503, 67, 37.3, 11.5, 2.3, 0.04311]",
                    "[Serum albumin pre-pro-protein, 4502027, 69, 986.0, 332.8, 2.4, 0.00006]",
                    "[Vitamin D-binding protein isoform 1 precursor, 32483410, 53, 51.9, 19.2, 2.4, 0.03919]",
                    "[Kininogen-1 isoform 2 precursor, 4504893, 48, 21.3, 5.5, 3.8, 0.01109]",
                    "[Alpha-2-macroglobulin precursor, 66932947, 163, 127.9, 29.3, 3.9, 0.00618]",
                    "[Haptoglobin isoform 1 pre-pro-protein, 4826762, 45, 83.8, 18.0, 4.2, 0.00024]",
                    "[Fibrinogen gamma chain isoform gamma-B precursor, 70906439, 52, 89.3, 17.3, 4.3, 0.00133]",
                    "[Complement C3 precursor, 115298678, 187, 174.7, 35.6, 4.3, 0.00612]",
                    "[Myeloperoxidase precursor, 4557759, 84, 70.2, 11.0, 5.3, 0.02501]",
                    "[Apolipoprotein A-I pre-pro-protein, 4557321, 31, 29.8, 5.9, 5.7, 0.02170]",
                    "[Fibrinogen alpha chain isoform alpha-E pre-pro-protein, 4503689, 95, 63.3, 9.3, 6.4, 0.00031]",
                    "[Alpha-2-HS-glycoprotein pre-pro-protein, 156523970, 39, 7.3, 1.1, 6.5, 0.00173]",
                    "[Ceruloplasmin precursor, 4557485, 122, 47.3, 5.6, 7.5, 0.00114]",
                    "[PREDICTED: complement C4-A isoform 1, 341916194, 193, 32.1, 4.5, 7.7, 0.01791]",
                    "[Alpha-1B-glycoprotein precursor, 21071030, 54, 10.9, 1.2, 8.3, 0.00468]",
                    "[Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor, 31542984, 103, 5.5, 0.2, 35.4, 0.00484]",
                    "[Apolipoprotein B-100 precursor, 105990532, 516, 49.3, 1.0, 55.7, 0.02595]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "protein": "Fibrinogen gamma chain isoform gamma-B precursor",
                    "accession": "70906439",
                    "Molecural weight (MW) (kDa)": "52",
                    "statistical test": "t-test"
                },
                "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                "outcomes": "[89.3, 17.3, 4.3, 0.00133]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "technique": "mass spectrometry",
                    "comparison to": "controls",
                    "statistical representation": "average SC and NSAF ratio",
                    "replicates": "not specified"
                },
                "measures": "[protein name, accession number, MW, average SC, NSAF ratio, P-value]",
                "outcomes": [
                    "[Fibrinogen beta chain isoform 1 pre-pro-protein, 70906435, 56, 138.8, 52.1, 2.2, 0.01481]",
                    "[C4b-binding protein alpha chain precursor, 4502503, 67, 37.3, 11.5, 2.3, 0.04311]",
                    "[Serum albumin pre-pro-protein, 4502027, 69, 986.0, 332.8, 2.4, 0.00006]",
                    "[Vitamin D-binding protein isoform 1 precursor, 32483410, 53, 51.9, 19.2, 2.4, 0.03919]",
                    "[Kininogen-1 isoform 2 precursor, 4504893, 48, 21.3, 5.5, 3.8, 0.01109]",
                    "[Alpha-2-macroglobulin precursor, 66932947, 163, 127.9, 29.3, 3.9, 0.00618]",
                    "[Haptoglobin isoform 1 pre-pro-protein, 4826762, 45, 83.8, 18.0, 4.2, 0.00024]",
                    "[Fibrinogen gamma chain isoform gamma-B precursor, 70906439, 52, 89.3, 17.3, 4.3, 0.00133]",
                    "[Complement C3 precursor, 115298678, 187, 174.7, 35.6, 4.3, 0.00612]",
                    "[Myeloperoxidase precursor, 4557759, 84, 70.2, 11.0, 5.3, 0.02501]",
                    "[Apolipoprotein A-I pre-pro-protein, 4557321, 31, 29.8, 5.9, 5.7, 0.02170]",
                    "[Fibrinogen alpha chain isoform alpha-E pre-pro-protein, 4503689, 95, 63.3, 9.3, 6.4, 0.00031]",
                    "[Alpha-2-HS-glycoprotein pre-pro-protein, 156523970, 39, 7.3, 1.1, 6.5, 0.00173]",
                    "[Ceruloplasmin precursor, 4557485, 122, 47.3, 5.6, 7.5, 0.00114]",
                    "[PREDICTED: complement C4-A isoform 1, 341916194, 193, 32.1, 4.5, 7.7, 0.01791]",
                    "[Alpha-1B-glycoprotein precursor, 21071030, 54, 10.9, 1.2, 8.3, 0.00468]",
                    "[Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor, 31542984, 103, 5.5, 0.2, 35.4, 0.00484]",
                    "[Apolipoprotein B-100 precursor, 105990532, 516, 49.3, 1.0, 55.7, 0.02595]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "protein": "Complement C3 precursor",
                    "accession": "115298678",
                    "Molecural weight (MW) (kDa)": "187",
                    "statistical test": "t-test"
                },
                "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                "outcomes": "[174.7, 35.6, 4.3, 0.00612]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "technique": "mass spectrometry",
                    "comparison to": "controls",
                    "statistical representation": "average SC and NSAF ratio",
                    "replicates": "not specified"
                },
                "measures": "[protein name, accession number, MW, average SC, NSAF ratio, P-value]",
                "outcomes": [
                    "[Fibrinogen beta chain isoform 1 pre-pro-protein, 70906435, 56, 138.8, 52.1, 2.2, 0.01481]",
                    "[C4b-binding protein alpha chain precursor, 4502503, 67, 37.3, 11.5, 2.3, 0.04311]",
                    "[Serum albumin pre-pro-protein, 4502027, 69, 986.0, 332.8, 2.4, 0.00006]",
                    "[Vitamin D-binding protein isoform 1 precursor, 32483410, 53, 51.9, 19.2, 2.4, 0.03919]",
                    "[Kininogen-1 isoform 2 precursor, 4504893, 48, 21.3, 5.5, 3.8, 0.01109]",
                    "[Alpha-2-macroglobulin precursor, 66932947, 163, 127.9, 29.3, 3.9, 0.00618]",
                    "[Haptoglobin isoform 1 pre-pro-protein, 4826762, 45, 83.8, 18.0, 4.2, 0.00024]",
                    "[Fibrinogen gamma chain isoform gamma-B precursor, 70906439, 52, 89.3, 17.3, 4.3, 0.00133]",
                    "[Complement C3 precursor, 115298678, 187, 174.7, 35.6, 4.3, 0.00612]",
                    "[Myeloperoxidase precursor, 4557759, 84, 70.2, 11.0, 5.3, 0.02501]",
                    "[Apolipoprotein A-I pre-pro-protein, 4557321, 31, 29.8, 5.9, 5.7, 0.02170]",
                    "[Fibrinogen alpha chain isoform alpha-E pre-pro-protein, 4503689, 95, 63.3, 9.3, 6.4, 0.00031]",
                    "[Alpha-2-HS-glycoprotein pre-pro-protein, 156523970, 39, 7.3, 1.1, 6.5, 0.00173]",
                    "[Ceruloplasmin precursor, 4557485, 122, 47.3, 5.6, 7.5, 0.00114]",
                    "[PREDICTED: complement C4-A isoform 1, 341916194, 193, 32.1, 4.5, 7.7, 0.01791]",
                    "[Alpha-1B-glycoprotein precursor, 21071030, 54, 10.9, 1.2, 8.3, 0.00468]",
                    "[Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor, 31542984, 103, 5.5, 0.2, 35.4, 0.00484]",
                    "[Apolipoprotein B-100 precursor, 105990532, 516, 49.3, 1.0, 55.7, 0.02595]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "protein": "Myeloperoxidase precursor",
                    "accession": "4557759",
                    "Molecural weight (MW) (kDa)": "84",
                    "statistical test": "t-test"
                },
                "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                "outcomes": "[70.2, 11.0, 5.3, 0.02501]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "technique": "mass spectrometry",
                    "comparison to": "controls",
                    "statistical representation": "average SC and NSAF ratio",
                    "replicates": "not specified"
                },
                "measures": "[protein name, accession number, MW, average SC, NSAF ratio, P-value]",
                "outcomes": [
                    "[Fibrinogen beta chain isoform 1 pre-pro-protein, 70906435, 56, 138.8, 52.1, 2.2, 0.01481]",
                    "[C4b-binding protein alpha chain precursor, 4502503, 67, 37.3, 11.5, 2.3, 0.04311]",
                    "[Serum albumin pre-pro-protein, 4502027, 69, 986.0, 332.8, 2.4, 0.00006]",
                    "[Vitamin D-binding protein isoform 1 precursor, 32483410, 53, 51.9, 19.2, 2.4, 0.03919]",
                    "[Kininogen-1 isoform 2 precursor, 4504893, 48, 21.3, 5.5, 3.8, 0.01109]",
                    "[Alpha-2-macroglobulin precursor, 66932947, 163, 127.9, 29.3, 3.9, 0.00618]",
                    "[Haptoglobin isoform 1 pre-pro-protein, 4826762, 45, 83.8, 18.0, 4.2, 0.00024]",
                    "[Fibrinogen gamma chain isoform gamma-B precursor, 70906439, 52, 89.3, 17.3, 4.3, 0.00133]",
                    "[Complement C3 precursor, 115298678, 187, 174.7, 35.6, 4.3, 0.00612]",
                    "[Myeloperoxidase precursor, 4557759, 84, 70.2, 11.0, 5.3, 0.02501]",
                    "[Apolipoprotein A-I pre-pro-protein, 4557321, 31, 29.8, 5.9, 5.7, 0.02170]",
                    "[Fibrinogen alpha chain isoform alpha-E pre-pro-protein, 4503689, 95, 63.3, 9.3, 6.4, 0.00031]",
                    "[Alpha-2-HS-glycoprotein pre-pro-protein, 156523970, 39, 7.3, 1.1, 6.5, 0.00173]",
                    "[Ceruloplasmin precursor, 4557485, 122, 47.3, 5.6, 7.5, 0.00114]",
                    "[PREDICTED: complement C4-A isoform 1, 341916194, 193, 32.1, 4.5, 7.7, 0.01791]",
                    "[Alpha-1B-glycoprotein precursor, 21071030, 54, 10.9, 1.2, 8.3, 0.00468]",
                    "[Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor, 31542984, 103, 5.5, 0.2, 35.4, 0.00484]",
                    "[Apolipoprotein B-100 precursor, 105990532, 516, 49.3, 1.0, 55.7, 0.02595]"
                ]
            },
            "Ground_truth_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "protein": "Apolipoprotein A-I pre-pro-protein",
                    "accession": "4557321",
                    "Molecural weight (MW) (kDa)": "31",
                    "statistical test": "t-test"
                },
                "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                "outcomes": "[29.8, 5.9, 5.7, 0.02170]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "technique": "mass spectrometry",
                    "comparison to": "controls",
                    "statistical representation": "average SC and NSAF ratio",
                    "replicates": "not specified"
                },
                "measures": "[protein name, accession number, MW, average SC, NSAF ratio, P-value]",
                "outcomes": "[Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor, 31542984, 103, 5.5, 0.2, 35.4, 0.00484]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "protein": "Fibrinogen beta chain isoform 1 pre-pro-protein",
                    "accession": "70906435",
                    "Molecural weight (MW) (kDa)": "56",
                    "statistical test": "t-test"
                },
                "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                "outcomes": "[138.8, 52.1, 2.2, 0.01481]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "technique": "mass spectrometry",
                    "comparison to": "controls",
                    "statistical representation": "average SC and NSAF ratio",
                    "replicates": "not specified"
                },
                "measures": "[protein name, accession number, MW, average SC, NSAF ratio, P-value]",
                "outcomes": "[Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor, 31542984, 103, 5.5, 0.2, 35.4, 0.00484]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "protein": "C4b-binding protein alpha chain precursor",
                    "accession": "4502503",
                    "Molecural weight (MW) (kDa)": "67",
                    "statistical test": "t-test"
                },
                "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                "outcomes": "[37.3, 11.5, 2.3, 0.04311]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "technique": "mass spectrometry",
                    "comparison to": "controls",
                    "statistical representation": "average SC and NSAF ratio",
                    "replicates": "not specified"
                },
                "measures": "[protein name, accession number, MW, average SC, NSAF ratio, P-value]",
                "outcomes": "[Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor, 31542984, 103, 5.5, 0.2, 35.4, 0.00484]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "protein": "Serum albumin pre-pro-protein",
                    "accession": "4502027",
                    "Molecural weight (MW) (kDa)": "69",
                    "statistical test": "t-test"
                },
                "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                "outcomes": "[986.0, 332.8, 2.4, 0.00006]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "technique": "mass spectrometry",
                    "comparison to": "controls",
                    "statistical representation": "average SC and NSAF ratio",
                    "replicates": "not specified"
                },
                "measures": "[protein name, accession number, MW, average SC, NSAF ratio, P-value]",
                "outcomes": "[Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor, 31542984, 103, 5.5, 0.2, 35.4, 0.00484]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "protein": "Vitamin D-binding protein isoform 1 precursor",
                    "accession": "32483410",
                    "Molecural weight (MW) (kDa)": "53",
                    "statistical test": "t-test"
                },
                "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                "outcomes": "[51.9, 19.2, 2.4, 0.03919]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "technique": "mass spectrometry",
                    "comparison to": "controls",
                    "statistical representation": "average SC and NSAF ratio",
                    "replicates": "not specified"
                },
                "measures": "[protein name, accession number, MW, average SC, NSAF ratio, P-value]",
                "outcomes": "[Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor, 31542984, 103, 5.5, 0.2, 35.4, 0.00484]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "protein": "Kininogen-1 isoform 2 precursor",
                    "accession": "4504893",
                    "Molecural weight (MW) (kDa)": "48",
                    "statistical test": "t-test"
                },
                "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                "outcomes": "[21.3, 5.5, 3.8, 0.01109]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "technique": "mass spectrometry",
                    "comparison to": "controls",
                    "statistical representation": "average SC and NSAF ratio",
                    "replicates": "not specified"
                },
                "measures": "[protein name, accession number, MW, average SC, NSAF ratio, P-value]",
                "outcomes": "[Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor, 31542984, 103, 5.5, 0.2, 35.4, 0.00484]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "protein": "Alpha-2-macroglobulin precursor",
                    "accession": "66932947",
                    "Molecural weight (MW) (kDa)": "163",
                    "statistical test": "t-test"
                },
                "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                "outcomes": "[127.9, 29.3, 3.9, 0.00618]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "technique": "mass spectrometry",
                    "comparison to": "controls",
                    "statistical representation": "average SC and NSAF ratio",
                    "replicates": "not specified"
                },
                "measures": "[protein name, accession number, MW, average SC, NSAF ratio, P-value]",
                "outcomes": "[Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor, 31542984, 103, 5.5, 0.2, 35.4, 0.00484]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "protein": "Haptoglobin isoform 1 pre-pro-protein",
                    "accession": "4826762",
                    "Molecural weight (MW) (kDa)": "45",
                    "statistical test": "t-test"
                },
                "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                "outcomes": "[83.8, 18.0, 4.2, 0.00024]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "technique": "mass spectrometry",
                    "comparison to": "controls",
                    "statistical representation": "average SC and NSAF ratio",
                    "replicates": "not specified"
                },
                "measures": "[protein name, accession number, MW, average SC, NSAF ratio, P-value]",
                "outcomes": "[Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor, 31542984, 103, 5.5, 0.2, 35.4, 0.00484]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "protein": "Fibrinogen gamma chain isoform gamma-B precursor",
                    "accession": "70906439",
                    "Molecural weight (MW) (kDa)": "52",
                    "statistical test": "t-test"
                },
                "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                "outcomes": "[89.3, 17.3, 4.3, 0.00133]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "technique": "mass spectrometry",
                    "comparison to": "controls",
                    "statistical representation": "average SC and NSAF ratio",
                    "replicates": "not specified"
                },
                "measures": "[protein name, accession number, MW, average SC, NSAF ratio, P-value]",
                "outcomes": "[Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor, 31542984, 103, 5.5, 0.2, 35.4, 0.00484]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "protein": "Complement C3 precursor",
                    "accession": "115298678",
                    "Molecural weight (MW) (kDa)": "187",
                    "statistical test": "t-test"
                },
                "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                "outcomes": "[174.7, 35.6, 4.3, 0.00612]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "technique": "mass spectrometry",
                    "comparison to": "controls",
                    "statistical representation": "average SC and NSAF ratio",
                    "replicates": "not specified"
                },
                "measures": "[protein name, accession number, MW, average SC, NSAF ratio, P-value]",
                "outcomes": "[Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor, 31542984, 103, 5.5, 0.2, 35.4, 0.00484]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "protein": "Myeloperoxidase precursor",
                    "accession": "4557759",
                    "Molecural weight (MW) (kDa)": "84",
                    "statistical test": "t-test"
                },
                "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                "outcomes": "[70.2, 11.0, 5.3, 0.02501]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "technique": "mass spectrometry",
                    "comparison to": "controls",
                    "statistical representation": "average SC and NSAF ratio",
                    "replicates": "not specified"
                },
                "measures": "[protein name, accession number, MW, average SC, NSAF ratio, P-value]",
                "outcomes": "[Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor, 31542984, 103, 5.5, 0.2, 35.4, 0.00484]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "protein": "Fibrinogen alpha chain isoform alpha-E pre-pro-protein",
                    "accession": "4503689",
                    "Molecural weight (MW) (kDa)": "95",
                    "statistical test": "t-test"
                },
                "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                "outcomes": "[63.3, 9.3, 6.4, 0.00031]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "technique": "mass spectrometry",
                    "comparison to": "controls",
                    "statistical representation": "average SC and NSAF ratio",
                    "replicates": "not specified"
                },
                "measures": "[protein name, accession number, MW, average SC, NSAF ratio, P-value]",
                "outcomes": "[Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor, 31542984, 103, 5.5, 0.2, 35.4, 0.00484]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "protein": "Alpha-2-HS-glycoprotein pre-pro-protein",
                    "accession": "156523970",
                    "Molecural weight (MW) (kDa)": "39",
                    "statistical test": "t-test"
                },
                "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                "outcomes": "[7.3, 1.1, 6.5, 0.00173]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "technique": "mass spectrometry",
                    "comparison to": "controls",
                    "statistical representation": "average SC and NSAF ratio",
                    "replicates": "not specified"
                },
                "measures": "[protein name, accession number, MW, average SC, NSAF ratio, P-value]",
                "outcomes": "[Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor, 31542984, 103, 5.5, 0.2, 35.4, 0.00484]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "protein": "Ceruloplasmin precursor",
                    "accession": "4557485",
                    "Molecural weight (MW) (kDa)": "122",
                    "statistical test": "t-test"
                },
                "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                "outcomes": "[47.3, 5.6, 7.5, 0.00114]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "technique": "mass spectrometry",
                    "comparison to": "controls",
                    "statistical representation": "average SC and NSAF ratio",
                    "replicates": "not specified"
                },
                "measures": "[protein name, accession number, MW, average SC, NSAF ratio, P-value]",
                "outcomes": "[Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor, 31542984, 103, 5.5, 0.2, 35.4, 0.00484]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "protein": "PREDICTED: complement C4-A isoform 1",
                    "accession": "341916194",
                    "Molecural weight (MW) (kDa)": "193",
                    "statistical test": "t-test"
                },
                "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                "outcomes": "[32.1, 4.5, 7.7, 0.01791]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "technique": "mass spectrometry",
                    "comparison to": "controls",
                    "statistical representation": "average SC and NSAF ratio",
                    "replicates": "not specified"
                },
                "measures": "[protein name, accession number, MW, average SC, NSAF ratio, P-value]",
                "outcomes": "[Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor, 31542984, 103, 5.5, 0.2, 35.4, 0.00484]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "protein": "Alpha-1B-glycoprotein precursor",
                    "accession": "21071030",
                    "Molecural weight (MW) (kDa)": "54",
                    "statistical test": "t-test"
                },
                "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                "outcomes": "[10.9, 1.2, 8.3, 0.00468]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "technique": "mass spectrometry",
                    "comparison to": "controls",
                    "statistical representation": "average SC and NSAF ratio",
                    "replicates": "not specified"
                },
                "measures": "[protein name, accession number, MW, average SC, NSAF ratio, P-value]",
                "outcomes": "[Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor, 31542984, 103, 5.5, 0.2, 35.4, 0.00484]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                    "protein": "Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor",
                    "accession": "31542984",
                    "Molecural weight (MW) (kDa)": "103",
                    "statistical test": "t-test"
                },
                "measures": "[Average Spectral Count (SC)(Cancer), Average Spectral Count (SC)(Control), Normalized Spectral Abundance Factor (NSAF) ratio, P-value]",
                "outcomes": "[5.5, 0.2, 35.4, 0.00484]"
            },
            "match": "yes"
        }
    ],
    "total_extracted_claims": 2,
    "total_ground_truth_claims": 18,
    "number_of_matches": 2
}